Challenged claims of Sun Pharmaceutical Industries Inc.'s patent that relates to an adjustable illuminator that provides a uniform distribution of visible light in a number of configurations are unpatentable as obvious over prior art, the Patent Trial and Appeal Board determined, in an inter partes review by Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG. The board determined that the challenged claims are obvious over prior art directed to an apparatus and method for photodynamic treatment or diagnosis of actinic keratosis of the scalp or facial areas of a patient, and a treatment device which uses a ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.